Ocata Therapeutics Inc fka OCAT

[rocky301]

Research Grants $199,532..2008
Research Grants $204,439..2006
http://report.nih.gov/award/organizations.cfm?ot=&fy=2008&state=&ic=&fm=&orgid=4342501&view=orgdetail

plus

September 22, 2010, MARLBOROUGH, MA - Advanced Cell Technology, Inc. ("ACT”; OTCBB: ACTC) announced today that the company's Chief Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, of Harvard University and McLean Hospital, have won a National Institutes of Health (NIH) Director's Opportunity Award for research in "Translating Basic Science Discoveries into New and Better Treatments" under the American Recovery & Reinvestment Act of 2009. The NIH Award provides McLean Hospital and ACT's joint venture with CHA Biotech, Stem Cell & Regenerative Medicine International (SCRMI), $1.9 million to explore the potential of protein- induced pluripotent stem (iPS) cells as a source of universal red blood cells and platelets for transfusion.
http://www.advancedcell.com/news-and-media/press-releases/nih-awards-dr-lanza-act-dr-kwang-soo-kim-harvard-mclean-hospital-director-opportunity-award/index.asp